Clinical Trial Update: Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II [Phase 3]

View source ↗

Summary

Open-label Phase 3 pediatric trial evaluating safety, pharmacokinetics, and efficacy of Sebetralstat (KVD900) in children aged 2-11 with hereditary angioedema t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Sebetralstat (Sebetralstat)

Snippet

Sponsor: KalVista Pharmaceuticals, Ltd. | Conditions: Hereditary Angioedema | Phase 3 | Status: COMPLETED